Precision phagotherapy to treat bacterial infections
The search for antibiotics seems to have reached a peak for several decades, and it puts bacteriophages back at the forefront of the solutions to this problem.
Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. The Company has thus developed technologies, in compliance with current pharmaceutical standards, to select and produce active phages against resistant and multi-resistant bacteria.
Pherecydes has selected as priority targets three families of bacteria listed by the WHO as being among the most dangerous:Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. These three bacterial infections alone account for over 2/3 of hospital acquiredhospital acquired infections in industrialized countries.